newsimmune checkpoint inhibitorssurvival outcomes
MLH1 Promoter Hypermethylation Does Not Impact Survival Outcomes in dMMR Endometrial Cancer Treated with Immune Checkpoint Inhibitors
By MedXY|Aug 18, 2026
This study analyzes real-world data showing that MLH1 promoter hypermethylation and Lynch syndrome-associated genetic mutations confer similar response rates and survival outcomes in mismatch repair deficient endometrial cancer treated with
